WO2025243082 - COVALENT PROTEIN-PROTEIN INTERACTION INHIBITOR AGAINST SRPKS
National phase entry is expected:
Publication Number
WO/2025/243082
Publication Date
27.11.2025
International Application No.
PCT/IB2025/000238
International Filing Date
23.05.2025
Title **
[English]
COVALENT PROTEIN-PROTEIN INTERACTION INHIBITOR AGAINST SRPKS
[French]
INHIBITEUR D'INTERACTION PROTÉINE-PROTÉINE COVALENTE CONTRE DES SRPK
Applicants **
THE CHINESE UNIVERSITY OF HONG KONG
Inventors
NGO, Chi, Ki Jacky
XIA, Jiang
CAI, Gongli
BAO, Yishu
LI, Qinqyun
ZENG, Chuyue
Priority Data
63/651,527
24.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2262 | |
| EPO | Filing, Examination, Granting | 15505 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2463 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
27,277
Contact Us
Abstract[English]
Provided is a novel serine-arginine protein kinase (SRPK) inhibitor. More specifically, provided is the novel SRPK inhibitor C-DBS. The novel SRPK inhibitor C-DBS is a covalent protein-protein interaction inhibitor against SRPK and is used in methods oftreating cancers or viral infections.[French]
La présente invention concerne un nouvel inhibiteur de la sérine-arginine protéine kinase (SRPK). Plus spécifiquement, la présente invention concerne le nouvel inhibiteur de SRPK, C-DBS. Le nouvel inhibiteur de SRPK, C-DBS, est utilisé dans des méthodes de traitement de cancers ou d'infections virales.